Saito, H. Et Al. 2021. Durvalumab(D) +/- tremelimumab(T) plus platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN. ANNALS OF ONCOLOGY , vol.32 .

Saito, H., Goldman, J. W., Garassino, M. C., Chen, Y., Reinmuth, N., Hotta, K., ... Poltoratskiy, A.(2021). Durvalumab(D) +/- tremelimumab(T) plus platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN. ANNALS OF ONCOLOGY , vol.32.

Saito, Haruhiro Et Al. "Durvalumab(D) +/- tremelimumab(T) plus platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN," ANNALS OF ONCOLOGY , vol.32, 2021

Saito, Haruhiro Et Al. "Durvalumab(D) +/- tremelimumab(T) plus platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN." ANNALS OF ONCOLOGY , vol.32, 2021

Saito, H. Et Al. (2021) . "Durvalumab(D) +/- tremelimumab(T) plus platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN." ANNALS OF ONCOLOGY , vol.32.

@article{article, author={Haruhiro Saito Et Al. }, title={Durvalumab(D) +/- tremelimumab(T) plus platinum-etoposide(EP) in 1L ES-SCLC: Characterization of long-term benefit in CASPIAN}, journal={ANNALS OF ONCOLOGY}, year=2021}